THE ROLE OF CISPLATIN IN CHEMOTHERAPY OF ADVANCED BREAST-CANCER

Cisplatin containing regimens as first-line, second-line or as a third -line chemotherapy were administered in 26 and 36 patients, respective ly. The overall response rate in patients on first-line chemotherapy w as 53.9%, in patients on second or third line chemotherapy 30.6%. The differences both in overall and disease-free survival between patients on first-line and on second/third-line chemotherapy were statisticall y significant in favor of women treated with first-line chemotherapy ( p = 0.05). Hematologic and nonhematologic toxicities were mild to mode rate and were more pronounced in patients on second and third-line che motherapy. The overall response rate, DFS and OS were significantly be tter and longer in the group of patients treated with ''bolus'' CDDP i n comparison to the group of patients treated with CVI CDDP. Our resul ts confirm the activity of cisplatin-containing regimens (mainly CAP s chedules) in patients with advanced breast cancer not only as a first- line therapy but also in heavily pretreated patients by chemotherapy a nd/or radiation therapy and endocrine manipulation.